Tocilizumab for Renal Graft Inflammation
NCT02108600
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Late Complication From Kidney Transplant
Interventions
DRUG:
Tocilizumab
Sponsor
Flavio Vincenti